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a  b  s  t  r  a  c  t
Antimicrobial  resistance  (AMR)  is a growing  global  public  health  problem,  which  is  caused
by the  use  of antimicrobials  in  both  human  and  animal  medical  practice.  The objectives
of  the  present  cross-sectional  study  were  as follows:  (1) to determine  the  prevalence  of
resistance  in  Escherichia  coli isolated  from  the feces  of pets  from  the Porto  region  of  Portugal
against  19 antimicrobial  agents  and  (2)  to assess  the individual,  clinical  and  environmental
characteristics  associated  with  each  pet  as  risk  markers  for the  AMR  of the  E.  coli isolates.
From  September  2009  to  May  2012,  rectal  swabs  were  collected  from  pets  selected
using  a systematic  random  procedure  from  the ordinary  population  of  animals  attend-
ing the  Veterinary  Hospital  of  Porto  University.  A total  of 78  dogs  and 22  cats  were
sampled  with  the  objective  of isolating  E. coli.  The  animals’  owners,  who  allowed  the  col-
lection  of  fecal  samples  from  their  pets,  answered  a questionnaire  to  collect  information
about  the markers  that could  inﬂuence  the  AMR  of  the  enteric  E. coli.  Chromocult  tryp-
tone  bile  X-glucuronide  agar  was  used  for E.  coli isolation,  and  the  disk  diffusion  method
was  used  to determine  the antimicrobial  susceptibility.  The  data  were analyzed  using  a
multilevel,  univariable  and  multivariable  generalized  linear  mixed  model  (GLMM).  Sev-
eral (49.7%)  of the  396  isolates  obtained  in  this  study  were  multidrug-resistant.  The  E. coli
isolates exhibited  resistance  to  the  antimicrobial  agent’s  ampicillin  (51.3%),  cephalothin
(46.7%),  tetracycline  (45.2%)  and  streptomycin  (43.4%).  Previous  quinolone  treatment
was  the  main  risk  marker  for the  presence  of AMR  for 12  (ampicillin,  cephalothin,  cef-
tazidime,  cefotaxime,  nalidixic  acid,  ciproﬂoxacin,  gentamicin,  tetracycline,  streptomycin,
chloramphenicol,  trimethoprim–sulfamethoxazole  and  aztreonam)  of  the  15  antimicro-
bials  assessed.  Coprophagic  habits  were  also  positively  associated  with  an  increased  risk
of AMR  for six  drugs,  ampicillin,  amoxicillin–clavulanic  acid, cephamycin,  ciproﬂoxacin,
streptomycin,  and  trimethoprim–sulfamethoxazole.
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In  summary,  pets  with  a record  of one  or more  previous  quinolone  treatments  and  exhibit-
ing coprophagic  habits  were  at an  increased  risk  of harboring  multidrug-resistant  E.  coli
strains in  their  feces  compared  to pets  without  these  characteristics.  AMR  is a  serious  global
problem,  and  assessing  the risk markers  for the presence  of drug-resistant  bacteria  in pets,
a very  close  source  of  resistance  determinants  to  humans,  is essential  for the  implemen-
tation  of safe handling  procedures  for companion  animals  and  for the  prudent  selection  of















































environment (indoor habitat refers to those animals that. Introduction
Antimicrobial resistance (AMR) is one of the primary
lobal public health problems of the next decade (Carlet
t al., 2012). The main driving force of AMR, which is
ased on the genetic plasticity of bacteria, is the selec-
ive pressure exerted by antimicrobial usage in human and
eterinary medicine, animal and ﬁsh production, and agri-
ultural and food technology (Kearns, 2010; EAAD, 2013;
artins da Costa et al., 2013). Resistant bacteria may  be
ransmitted between interdependent hosts and spread into
he environment, contributing to the worldwide increase
f AMR (CDC, 2013). The progress in veterinary medicine
nd the number of domestic pets treated by specialized
ractitioners has increased the use of antimicrobial treat-
ents (Martins da Costa et al., 2013). Additionally, pets live
onger and are in closer contact with their owners, favor-
ng the mutual transfer of microbial ﬂora, either directly
y contact with skin or bacteria-containing material, such
s saliva and feces, or indirectly via the household envi-
onment (Martins et al., 2013). When introduced to a new
ost, the resistant bacteria can colonize, infect, or remain in
hat particular environment for very short periods of time.
n all cases, resistant bacteria can either spread their resis-
ance genes to host-resident bacteria, either commensals or
athogenic, or accept resistance genes from such microor-
anisms (Jernberg et al., 2010). As a consequence, AMR  in
ompanion animals is simultaneously an important vet-
rinary medical issue and a public health concern (Lloyd,
007).
The regular monitoring of AMR  in pathogenic and nor-
al  ﬂora has been recommended by the World Health
rganization and the European Centre for Disease Pre-
ention and Control. For this purpose, the European
ntimicrobial Resistance Surveillance Network (EARS-
et), involving 53 countries, was created (EFSA and ECDPC,
013). Similar programs have been proposed for veteri-
ary medicine, leading to ﬁeld studies of food animals
Aarestrup, 2004; Taylor et al., 2008) and pets (Moyaert
t al., 2006; Lloyd, 2007; Costa et al., 2008; Murphy et al.,
009; Leonard et al., 2012). However, to the best of our
nowledge, no studies have included the clinical histories
f both pets and their cohabitants and household features
o assess potential AMR risk markers.
Escherichia coli is an important member of the normal
ntestinal microﬂora of humans and other mammals, but it
s also a highly versatile pathogen, causing diverse intesti-
al and extra intestinal diseases via virulence factors that
ffect a wide range of cellular processes (Kaper et al., 2004).
MR  has been associated with several treatment failures in©  2014  Elsevier  B.V.  All  rights  reserved.
both human and veterinary patients (Toutain et al., 2010;
Vigil et al., 2009).
The objective of the present study was  to determine the
proportion of antimicrobial-resistant E. coli isolated from
the feces of pets from the Porto region of Portugal and to
assess the individual, clinical and environmental charac-
teristics of pets as risk markers for the AMR  in the isolated
strains. It is hypothesized that animals with a relevant clin-
ical background will harbor more resistant E. coli isolates.
2. Materials and methods
2.1. Enrollment and sampling
Only dogs and cats were enrolled in the study. A ran-
dom systematic approach was  used to select animals for
the present cross-sectional study, which was  performed at
the Veterinary Hospital of Porto University (UPVET).
From September 2009 to May  2012, on Monday or
Tuesday, one of the ﬁrst ﬁve pets to arrive at the UPVET
attending room was randomly selected for inclusion in the
study. If the owners refused to participate in the study,
the next pet, in order of arrival, was  included. To be eli-
gible for enrollment in the study, the animal should not
have received any antimicrobial therapy within the pre-
ceding 4 months. The owners were asked to sign a consent
form, ﬁll out a questionnaire and allow the collection of
fecal samples from their pets using rectal swabs. The Ethics
Committee of the Abel Salazar Institute for the Biomedical
Sciences, University of Porto approved this study.
2.2. Questionnaire
The owners were asked to ﬁll out a brief questionnaire
to provide information about the possible risk mark-
ers for multidrug-resistant E. coli. Multidrug resistance
was deﬁned according to Magiorakos et al. (2012). The
questionnaire was  conducted by the ﬁrst author and con-
structed following similar studies in animals (Akwar et al.,
2007; Ahmed et al., 2012; Boothe, 2012) and humans
(McDonald et al., 2001; Sotto et al., 2001; Lietzau et al.,
2007; Kalter et al., 2010; Lastours et al., 2010). To evalu-
ate the potential risk markers, the questionnaires included
the following individual and clinical characteristics: (1)
species, (2) gender, (3) age, (4) daily access to the outsidelive predominantly at home or with very restricted out-
door access), (5) diet (commercial refers to the animals
that were fed strictly commercial dry or wet foods), (6)
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coprophagic habits (ingestion of feces, both their own or
from other animals), (7) previous systemic antimicrobial
treatments with particular emphasis on (8) previous sys-
temic quinolone treatments (assessed through the clinical
ﬁle of the pet), (9) existence of cohabitant pets in the house-
hold, (10) previous antimicrobial treatments received by
the owners, (11) owner’s professional connection with
healthcare units, such as human or veterinary hospitals,
clinics or health centers (such owners were classiﬁed as
Health Professionals), and (12) reason for veterinary visit
(recorded by the veterinary surgeon following a complete
physical examination).
2.3. E. coli isolation
Fecal samples were obtained using saline wet swabs
that were introduced with circular movements into the
rectum of each animal. The swabs were immediately
immersed in buffered peptone water (BPW) (Oxoid,
Basingstoke, Hampshire, England), transported to the lab-
oratory and stored at room temperature for 1 h. Then,
for E. coli isolation, an aliquot of 5 L was streaked onto
Chromocult tryptone bile X-glucuronide (TBX) agar (Biokar
Diagnostics, Allonne, Beauvais, France) and incubated at
37 ◦C for 24 h. Two to ﬁve conﬁrmed pure colonies with
a typical appearance of E. coli were selected on the basis of
colony size and morphology. The described procedure and
the biochemical conﬁrmation of the isolates were adapted
from standard protocols used in similar studies to achieve
the most reliable and accurate E. coli detection (Costa et al.,
2008; Simões et al., 2010; Martins et al., 2013).
2.4. Antimicrobial susceptibility characterization
A disk diffusion assay following the standard guidelines
(CLSI, 2012) was performed to assess the antimicrobial sus-
ceptibility of each isolate. The antimicrobial drugs were
selected to include those regularly used in both human
and veterinary medicine and to represent different antimi-
crobial classes (Goossens et al., 2005; Elseviers et al.,
2007; EFSA and ECDPC, 2013). A total of 19 antimicro-
bial agents (AM) (Oxoid, Basingstoke, Hampshire, England)
were used: ampicillin (AMP, 10 g), amoxicillin–clavulanic
acid (AMC, 30 g), cephalothin (CEF, 30 g), cefox-
itin (FOX, 30 g), ceftazidime (CAZ, 30 g), cefotaxime
(CTX, 30 g), nalidixic acid (NAL, 30 g), ciproﬂoxacin
(CIP, 5 g), gentamicin (GEN, 10 g), tetracycline (TET,
30 g), streptomycin (STR, 10 g), amikacin (AMK, 30 g),
trimethoprim–sulfamethoxazole (SXT, 25 g), chloram-
phenicol (CHL, 30 g), tobramycin (TOB, 10 g), kanamycin
(KAN, 30 g), aztreonam (ATM, 30 g), imipenem (IPM,
10 g), and nitrofurantoin (NIT, 300 g). The interpretation
of the inhibition zone length was based on the recommen-
dations of the Clinical and Laboratory Standards Institute
(CLSI) and breakpoints for Enterobacteriaceae (CLSI, 2012).
2.5. Data analysisThe prevalence of AMR  for each AM was calculated
by dividing the number of resistant E. coli isolates by the
total number of E. coli tested. The potential risk markersnary Medicine 117 (2014) 28–39
obtained from the questionnaire were analyzed as cate-
gorical variables as follows: dichotomous variables, such
as species (canine, feline), gender (male, female), reason
for veterinary visit (routine check-up, illness signs), habitat
type (indoor, mixed), diet (commercial, mixed), previ-
ous quinolone treatments (yes, no), health professional
owners (yes, no), owners administered previous antimi-
crobial treatments (yes, no), cohabitant pets (yes, no),
coprophagy habits (yes, no), and exposure of the animal
to any previous antimicrobial treatment, which was  trans-
formed into a categorical variable with three levels: “none”,
“just one”, and “two or more”. Age was also categorized
using three levels as follows: “young” (less than 2 years of
age), “adult” (between 2 and 10 years of age), and “old”
(greater than 10 years of age). The outcome of the analy-
sis was the result of the AMR, which was dichotomized as
either resistant or sensitive. The intermediate results were
categorized as sensitive. Using the European Food Safety
Authority criteria, each antimicrobial was further classi-
ﬁed into one of the following categories for the prevalence
of AMR: extremely high, >70%; very high, 50–70%; high,
20–50%; moderate, 10–20%; low, 1–10%; very low, 0.1–1%;
and rare, <0.1% (EFSA and ECDPC, 2013).
A descriptive analysis of AMR  prevalence and the risk
markers distribution among E. coli isolates was performed
(Table 4). To assess the strength of associations between
the suggested risk markers and each AM (n = 15), multilevel
generalized linear mixed models (GLMM)  were developed.
The logit link function was used to model the probability of
occurrence of resistance to an antibiotic. For the multilevel
structure of the data, i.e., more than one E. coli strain (i)
was isolated from each animal (j), a two-level structure, in
which the E. coli strains (ﬁrst level) were nested within the
animal from which they were isolated (second level), was
assumed.





where Y is the response vari-
able.Pr(Y) = pij, i = 1, . . .,  396 and j = 1, . . .,  100.
The generic model used the following equation:
logit(pij) = a + cj +  ˇ animal variablesj
In the model, the animal (pet) was allowed to be ran-
dom. The second-level random effect was  given by cj ∼ N(0,
2), where 2 is the variance of the random effects at the
animal level.
The basic multivariable multilevel model was as fol-
lows:
logit(pij) = a + cj + ˇ1Speciesj + ˇ2Agej + ˇ3Genderj
+ ˇ4Reason for visitj + ˇ5Habitatj + ˇ6Dietj
+ ˇ7Number AM treatmentsjˇ8
Previous Qutnolone treatmentsj+ˇ9Owner’s professionj|ˇ10
Owner’s AM treatmentsj|ˇ11
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 three-step procedure was performed. Firstly, for each
f the evaluated antimicrobials, an univariable multilevel
LMM analysis was conducted to assess the individual
elationship between each potential risk factor and the
resence of AMR. The second step involved a multivari-
ble multilevel GLMM analysis with all of the variables with
 < 0.15 in the previous analyses. In the third step, a man-
al backwards and forwards procedure was used to obtain a
nal model in which each factor effect was adjusted for the
emaining factors. Only factors with p < 0.05 were retained
n the ﬁnal model. Two way interactions were tested for the
actors retained in each ﬁnal model. The data were analyzed
sing the GEE procedure in the SPSS Software V. 21.0 (IBM
PSS statistical 21 package, IBM Corporation, NY, USA).
nteractions were tested and found to be not signiﬁcant.
The procedure explained above was applied to the 15
M resulting in 15 different ﬁnal models, although based
n the same general model.
. Results
A total of 78 dogs and 22 cats from 100 distinct house-
olds were enrolled. Overall, 396 E. coli isolates were
btained, 307 (77.5%) isolated from dogs and 89 (22.5%)
solated from cats. Between two and ﬁve isolates were
btained per pet with a median of 2 isolates per animal..1. Antimicrobial resistance proﬁles
Our results showed that 28.8% of the isolates were
usceptible to all of the tested compounds. It was  also
Fig. 1. Frequency of antimicrobial resistancenary Medicine 117 (2014) 28–39 31
observed that 50% of the isolates (median) had up to three
antimicrobial resistances; ﬁnally, it was  noticed that 75%
(third quartile) of the isolates were resistant to at most
seven drugs. Extreme resistance toward 14 or 15 AMs  was
observed in ﬁve isolates (1.3%) (data not shown). The his-
togram displaying the absolute number antimicrobials to
which the isolates were resistant suggests the existence
of two  or possibly three subpopulations of E. coli (Fig. 1):
one group was  resistant to at most four antimicrobials, the
second group was  resistant to 5–10 antimicrobials, and
a possible third group with isolates having more than 10
antimicrobial resistances.
3.2. Prevalence of antimicrobial resistance
The prevalence of AMR  varied from 0% for nitrofurantoin
and imipenem to 51.3% (±0.049) for ampicillin. After cat-
egorization according to the EFSA (EFSA and ECDPC, 2013)
recommendations, 5.3% (±0.022) of the tested AMs were in
the very high resistance category, 31.6% (±0.046) were in
the high resistance group, and a similar proportion were in
the moderate resistance category, as shown in Table 1.
3.3. Distribution of potential risk markers associated
with pets
The frequency of each tested potential risk marker is
shown in Table 2. After looking at the factors species, age,
sex and reason for visit it was concluded that the popu-
lation of pets enrolled in our study resembled fairly the
population of cats and dogs attending the hospital.
 in Escherichia coli isolates (n = 396).
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Table  1
Categorization of the antimicrobials (AM) tested with Escherichia coli isolates (n = 396) according to the EFSA risk categories for the prevalence of resistance.
EFSA risk categories AM Prevalence of resistance Conﬁdence interval
Extremely high 0.0 – –
Very  high AMP  51.3 51.251 51.349
High
CEF  46.7 46.651 46.749
NAL  35.9 35.853 35.947
CIP 29.5 29.455 29.545
TET 45.2 45.151 45.249
STR  43.4 43.351 43.449
SXT  36.4 36.353 36.447
Moderate
AMC  12.1 12.068 12.132
CAZ  13.6 13.566 13.634
CTX  14.6 14.565 14.635
CHL  18.2 18.162 18.238
KAN  13.9 13.866 13.934
ATM  17.7 17.662 17.738
Low
FOX 5.8 5.777 5.823
GEN  5.8 5.777 5.823
TOB  3.0 2.983 3.017
Very  low AMK  0.5 0.493 0.507
Rare
NIT  0.0 – –
IPM  0.0 – –
Legend: AM – antimicrobial agent; C.I. – Conﬁdence interval; AMP  – ampicillin; AMC – amoxicillin–clavulanic acid; CEF – cephalothin; FOX – cephoxitin; CAZ
–  ceftazidime; CTX – cefotaxime; NAL – nalidixic acid; CIP – ciproﬂoxacin; GEN – gentamicin; NIT – nitrofurantoin; TET – tetracycline; STR – streptomycin;
AMK  – amikacin; SXT – trimethoprim–sulfamethoxazole; CHL – chloramphenicol; TOB – tobramycin; KAN – kanamycin; IPM – imipenem; ATM – aztreonam.
The  values are expressed in percentages.
Table 2
Distribution of the potential risk marker categories among pets (n = 100).
Risk marker Category Dogs % Dogs Cats % Cats Dogs + cats
Species 78 22 100
Age  <2 years 24 30 9 40 33
2–10 years 34 43 11 50 45
>10 years 20 25 2 9 22
Gender Female 47 60 9 40 56
Male 31 39 13 59 44
Reason for veterinary visit Check up 23 29 15 68 38
Illness 55 70 7 31 62
Habitat type Indoor 9 11 15 68 24
Mixed 69 88 7 31 76
Diet  Commercial 25 32 10 45 35
Mixed 53 67 12 54 65
Animal antimicrobial treatments None 21 26 17 77 38
Just one 19 24 3 13 22
Two/more 38 48 2 9 40
Animal quinolone treatments Yes 28 35 2 9 30
No  50 64 20 90 70
Owners health professionals Yes 16 20 6 27 22
No 62 79 16 72 78
Owners antimicrobial treatments Yes 38 48 6 27 44
No 40 51 16 72 56
Cohabitant pets Yes 36 46 16 72 52
No 42 53 6 27 48
Coprophagy habits Yes 29 37 4 18 33
No 49 62 18 81 67
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Table  3
Distribution of the Escherichia coli isolates (n = 396) of canine (n = 307) and feline (n = 89) origin by potential risk marker categories.
Risk marker Category Canine isolates Feline isolates Total isolates (%)
Age <2 years 85 32 117 (29.5)
2–10 years 135 51 186 (47.0)
>10 years 87 6 93 (23.5)
Gender Female 185 37 222 (56.1)
Male 122 52 174 (43.9)
Reason for veterinary visit Check up 81 64 145 (36.6)
Illness 226 25 251 (63.4)
Habitat type Indoor 35 59 94 (23.7)
Mixed 272 30 302 (76.3)
Diet  Commercial 107 34 141 (35.6)
Mixed 200 55 255 (64.4)
Animal antimicrobial treatments None 71 67 138 (34.8)
Just one 69 12 81 (20.5)
Two or more 167 10 177 (44.7)
Animal quinolone treatments Yes 121 10 131 (33.1)
No 186 79 265 (66.9)
Owners health professionals Yes 65 27 92 (23.2)
No 242 62 304 (76.8)
Owners antimicrobial treatments Yes 162 25 187 (47.2)
No 145 64 209 (52.8)
Cohabitant pets Yes 142 66 208 (52.5)


























nCoprophagy habits Yes 
No 
Twenty-three dogs (29.5%) and 15 cats (68.2%) were
ealthy animals admitted for regular check-ups or prophy-
actic actions, whereas the remaining animals attended the
ospital for clinical reasons.
.4. Distribution of potential risk markers among E. coli
solates
The distribution of potential risk markers among the
. coli isolates is displayed in Table 3. The largest numbers of
solates were obtained from pets owned by non-health pro-
essionals (n = 304; 76.8%) and animals with outdoor access
n = 302; 76.3%). The characteristics that were associated
ith a small proportion of isolates were having only one
ntimicrobial treatment (n = 81; 20.5%), age greater than
0 years (n = 93; 23.5%) and living indoors (n = 94; 23.7%).
.5. Antimicrobial resistance and potential risk markers
The frequencies of AMR  for each potential risk marker
re shown in Table 4. No isolate displayed resistance to
itrofurantoin or imipenem which were for this reason
xcluded from further statistical analyses. The AMR  pro-
ortions were calculated based on all of the isolates (396).
he lowest AMR  rates were found in young indoor ani-
als nourished with a commercial diet and subjected to
 single previous antimicrobial treatment. In this group,
here were no isolates resistant to amoxicillin–clavulanic
cid and cephoxitin, and no cephoxitin-resistant isolates
ere found in cats or in young or indoor animals. Finally,
o cefotaxime-resistant isolates were found in cats, and no 18 137 (34.6)
 71 259 (65.4)
gentamicin-resistant isolates were recovered from animals
fed a commercial diet.
3.6. Results of the multilevel univariable analysis
Table 5 displays the results of the multilevel univari-
able analysis. Only the odds ratios (ORs) for the variables
and categories in which the p value was less than 0.15
are shown. There were no signiﬁcant associations between
the risk markers assessed and AMR  for amikacin and
tobramycin; therefore, these were not included in the sub-
sequent multilevel multivariable analysis. For this reason
only 15 AM were tested in this analysis.
3.7. Results of the multilevel multivariable analysis
The ﬁnal models were obtained through a multilevel
multivariate analysis after manual backwards and forwards
variable selection. The variables retained after adjustment
are the ones which remained signiﬁcant at p < 0.05 and are
presented in Table 6. There were no interactions among
variables for none of the 15 AM tested.
In this analysis, ampicillin was  the antimicrobial agent
positively associated with the highest number of markers
(5 of 12 markers), including species (canine), gender (male),
previous quinolone treatment, having owners that were
health professionals and coprophagic habits. Resistances
to amoxicillin–clavulanic acid and chloramphenicol were
both signiﬁcantly associated with three and two different
markers, respectively. Resistances to ciproﬂoxacin, strep-
tomycin and trimethoprim–sulfamethoxazole showed an
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Table  4
Percentage of antimicrobial resistance distributed by categories of potential risk markers.
Risk markers AMP  AMC  CEF FOX CAZ CTX NAL CIP GEN TET STR SXT CHL KAN ATM
Species canine 58.3 15.0 53.1 7.5 14.7 18.9 39.1 35.2 7.2 47.6 45.6 39.4 20.2 14.0 20.8
Species  feline 27.0 2.2 24.7 0.0 10.1 0.0 24.7 10.1 1.1 37.1 36.0 25.8 11.2 13.5 6.7
Age:  <2 years 47.0 2.6 37.6 0.0 11.1 14.5 25.6 25.6 1.7 35.9 35.0 30.8 12.8 6.0 16.2
Age:  2–10 years 44.6 9.1 40.3 5.4 10.2 12.4 35.5 28.5 5.4 45.2 44.6 34.9 18.8 17.2 14.0
Age:  >10 years 69.9 30.1 71.0 14.0 23.7 19.4 49.5 36.6 11.8 57.0 51.6 46.2 23.7 17.2 26.9
Gender  female 45.0 10.8 44.1 4.1 11.3 14.4 34.2 27.5 6.3 45.5 40.1 36.0 11.3 14.9 16.7
Gender  male 59.2 13.8 50.0 8.0 16.7 14.9 37.9 32.2 5.2 44.8 47.7 36.8 27.0 12.6 19.0
Reason:  check up 38.6 4.1 30.3 1.4 4.8 3.4 23.4 17.2 1.4 34.5 30.3 33.1 9.7 11.7 6.9
Reason:  illness 58.6 16.7 56.2 8.4 18.7 21.1 43.0 36.7 8.4 51.4 51.0 38.2 23.1 15.1 23.9
Habitat: indoor 37.2 2.1 33.0 0.0 13.8 4.3 39.4 25.5 2.1 48.9 41.5 23.4 20.2 17.0 11.7
Habitat: mixed 55.6 15.2 51.0 7.6 13.6 17.9 34.8 30.8 7.0 44.0 44.0 40.4 17.5 12.9 19.5
Diet:  commercial 44.7 12.8 46.1 9.2 16.3 11.3 34.0 24.1 0.0 44.7 34.0 34.0 13.5 5.7 16.3
Diet:  mixed 54.9 11.8 47.1 3.9 12.2 16.5 36.9 32.5 9.0 45.5 48.6 37.6 20.8 18.4 18.4
AM  Tx: none 40.6 5.1 32.6 0.7 4.3 6.5 18.1 13.8 3.6 31.2 29.0 29.7 10.9 11.6 6.5
AM  Tx: one 45.7 0.0 40.7 0.0 11.1 17.3 44.4 44.4 7.4 48.1 43.2 38.3 19.8 16.0 22.2
AM  Tx: 2 or + 62.1 23.2 60.5 12.4 22.0 19.8 45.8 35.0 6.8 54.8 54.8 40.7 23.2 14.7 24.3
Quinolone Tx: yes 77.1 19.1 69.5 12.2 32.8 33.6 67.2 56.5 13.0 63.4 64.9 51.1 34.4 21.4 42.0
Quinolone Tx: no 38.5 8.7 35.5 2.6 4.2 5.3 20.4 16.2 2.3 36.2 32.8 29.1 10.2 10.2 5.7
O.  Prof.: health prof. 65.2 23.9 55.4 6.5 7.6 7.6 37.0 34.8 1.1 56.5 55.4 53.3 19.6 10.9 10.9
O.  Prof.: others 47.0 8.6 44.1 5.6 15.5 16.8 35.5 28.0 7.2 41.8 39.8 31.2 17.8 14.8 19.7
O.  AM Tx: yes 54.5 15.0 50.8 6.4 14.4 18.7 43.9 36.9 9.1 47.6 50.8 40.1 19.8 16.0 19.3
O.  AM Tx: no 48.3 9.6 43.1 5.3 12.9 11.0 28.7 23.0 2.9 43.1 36.8 33.0 16.7 12.0 16.3
Cohabit. pets: yes 51.4 15.9 45.7 7.7 13.0 17.8 38.5 34.1 7.7 46.6 46.6 43.3 20.2 15.4 21.2
Cohabit. pets: no 51.1 8.0 47.9 3.7 14.4 11.2 33.0 24.5 3.7 43.6 39.9 28.7 16.0 12.2 13.8
Coprophagy: yes 67.9 26.3 56.9 13.1 19.7 22.6 48.9 42.3 10.9 57.7 57.7 54.0 23.4 16.8 27.7
Coprophagy: no 42.5 4.6 41.3 1.9 10.4 10.4 29.0 22.8 3.1 38.6 35.9 27.0 15.4 12.4 12.4
Legend: AM – antimicrobial; TX – treatment; O. – owner; Prof. – professional; Cohabit. – cohabitant; AMP  – ampicillin; AMC – amoxicillin–clavulanic acid;
; NAL – n
oxazoleCEF  – cephalothin; FOX – cephoxitin; CAZ – ceftazidime; CTX – cefotaxime
TET  – tetracycline; STR – streptomycin; SXT – trimethoprim–sulfameth
aztreonam.
association with two similar markers, namely previous
quinolone treatment and coprophagic habits, whereas
AMR  to cephalothin, ceftazidime, cefotaxime, nalidixic
acid, gentamycin, tetracycline, and aztreonam retained
one signiﬁcant association (previous quinolone treat-
ment). Finally, cephoxitin resistance was associated with
coprophagy, and kanamycin resistance was positively asso-
ciated with a mixed diet.
Previous quinolone treatments and coprophagic habits
were signiﬁcantly related to AMR  for 12 and 6 of the
15 antimicrobial agents tested, respectively. According
to the model, pets that received quinolone treatments
have a signiﬁcantly higher risk of colonization by E.
coli resistant to ceftazidime (OR 16.78 (2.33–120.74)),
cefotaxime (OR 22.01 (13.15–154.01)), nalidixic acid
(OR 13.51 (3.83–47.61)) and aztreonam (OR 19.18
(3.67–100.14)). Animals with coprophagic habits are at
a higher risk of harboring E. coli isolates resistant to
amoxicillin–clavulanic acid (OR 10.35 (2.34–45.76)) and
cephoxitin (OR 11.21 (1.26–99.64)) (Table 6). Overall, the
risk markers signiﬁcantly associated with AMR  were the
following: (i) previous treatment with quinolones (12
of 15) and (ii) coprophagic habits (6 of 15). The fol-
lowing variables were only sporadically associated with
AMR  to some antimicrobials: (i) canine species (ampi-
cillin); (ii) male gender (ampicillin and chloramphenicol);alidixic acid; CIP – ciproﬂoxacin; GEN – gentamicin; NIT – nitrofurantoin;
; CHL – chloramphenicol; KAN – kanamycin; IPM – imipenem; ATM –
(iii) illness (amoxicillin–clavulanic acid and chlorampheni-
col); (iv) mixed diet (kanamycin) and (v) health profes-
sional owners (ampicillin and amoxicillin–clavulanic acid).
4. Discussion
Given the remarkable increase in AMR  worldwide and
the enormous difﬁculties and unsuccessful strategies to
prevent resistance, it is important to identify resistance
risk factors. The present study was designed to assess the
prevalence of AMR  in enteric E. coli isolated from domestic
cats and dogs in Porto, Portugal and to identify the poten-
tial risk markers for the presence of AMR  in those isolates.
This was accomplished with a GLMM because of the mul-
tilevel structure of the data. The inspection of the address
information of the owners enrolled in the study showed no
evidence of geographical clustering.
The proportions of AMR  observed against ampicillin,
cephalothin, tetracycline, streptomycin, trimethoprim–
sulfamethoxazole, nalidixic acid, and ciproﬂoxacin were
higher than previously reported (Costa et al., 2008;
Murphy et al., 2009; Leonard et al., 2012). According to
the categories proposed by the EFSA (EFSA and ECDPC,
2013), 36.9% of the AMs  tested were in the high or very
high resistance groups (Table 1). Interestingly, none of



















Risk markers for the antimicrobial resistance of E. coli isolates from the univariable multilevel analysis.
Risk markers AMP  AMC  CEF FOX CAZ CTX NAL CIP GEN TET STR SXT CHL KAN ATM
OR  OR OR OR OR OR OR OR OR OR OR OR OR OR OR
Species canine 6.63** 7.08 5.37** 2.43 5.83* 4.76
Species  feline
Age: <2 years 0.3 0.06** 0.14** 0.42 0.26 0.53 0.29
Age:  2–10 years 0.24* 0.17* 0.16** 0.28 0.46 0.61 0.52
Age:  >10 years
Gender female 0.4 0.25*
Gender male
Reason: check up 0.30* 0.22* 0.23** 0.26 0.14* 0.35* 0.32* 0.36* 0.30* 0.36 0.23*
Reason:  ilness
Habitat: indoor 0.31 0.13 0.33 0.16 0.38
Habitat: mixed
Diet: commercial 0.42 0.24∗
Diet:  mixed
AM Tx: none 0.30* 0.19* 0.21** 0.10 0.17* 0.26 0.20** 0.25* 0.24* 0.22** 0.19*
AM  Tx: one 0.35 0.00 0.31 0.00 0.41 0.78 0.89 1.59 0.66 0.475 0.97
AM  Tx: 2 or +
Quinolone Tx: yes 10.01*** 7.71*** 4.5 15.94*** 13.84*** 14.92*** 12.28*** 4.73∗ 4.76** 6.98*** 3.43* 6.42** 2.4 20.79***
Quinolone Tx: no
O. Prof.: health prof. 2.7 4.69*
O. Prof.: others
O. AM Tx: yes 2.51 2.23 2.65
O.  AM Tx: no
Cohabit. Pets: yes
Cohabit. Pets: no
Coprophagy: yes 4.14** 10.43** 2.39 10.98* 3.22 3.22* 3.61* 3.81 3.07* 3.79* 4.77** 3.43*
Coprophagy: no
Risk markers for the antimicrobial resistance of E. coli isolates from the univariable multilevel analysis.
Legend: OR – the odds ratio signiﬁcance level is indicated by the number of asterisks as follows: *0.01 ≤ p < 0.05; **0.001 ≤ p < 0.01; ***p < 0.001; AM – antimicrobial; TX – treatment; O.  – owner; Prof. – professional;
Health  prof. – healthcare professional; Cohabit. – cohabitant; AMP  – ampicillin; AMC  – amoxicillin–clavulanic acid; CEF – cephalothin; FOX – cephoxitin; CAZ – ceftazidime; CTX – cefotaxime; NAL – nalidixic
acid;  CIP – ciproﬂoxacin; GEN – gentamicin; NIT – nitrofurantoin; TET – tetracycline; STR – streptomycin; SXT – trimethoprim–sulfamethoxazole; CHL – chloramphenicol; KAN – kanamycin; IPM – imipenem;
ATM  – aztreonam.
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Table  6
Final results with risk markers for the antimicrobial resistance of E. coli isolates (n = 396) from the multilevel multivariable analysis.
AM Risk marker AMR+ OR CI p Value
AMP  Species canine 179 5.16 1.49–17.85 0.010
Gender female 100 0.35 0.13–0.95 0.039
Previous quinolone tx. 101 6.02 2.02–17.89 0.001
O.  Health prof. 60 3.95 1.23–12.70 0.021
Coprophagy 93 2.80 1.02–7.67 0.045
AMC  Reason Check up 6 0.16 0.03–0.98 0.047
O.  Health prof. 22 6.41 1.34–29.88 0.018
Coprophagy 36 10.35 2.34–45.76 0.002
CEF  Previous quinolone tx. 91 4.68 1.15–19.10 0.032
FOX  Coprophagy 18 11.21 1.26–99.64 0.030
CAZ  Previous quinolone tx. 43 16.78 2.33–120.74 0.005
CTX  Previous quinolone tx. 44 22.01 13.15–154.01 0.002
NAL  Previous quinolone tx. 88 13.51 3.83–4.61 0.000
CIP  Previous quinolone tx. 74 9.05 2.62–31.30 0.001
Coprophagy 58 3.12 1.05–9.29 0.040
GEN  Previous quinolone tx 17 4.73 1.02–22.81 0.049
TET  Previous quinolone tx 83 4.20 1.46–12.07 0.008
STR  Previous quinolone tx 85 4.55 1.29–16.09 0.019
Coprophagy 79 3.20 1.09–9.45 0.035
SXT  Previous quinolone tx 67 2.87 1.05–7.78 0.039
Coprophagy 74 3.73 1.32–10.48 0.013
CHL  Gender female 25 0.28 0.09–0.93 0.038
Previous quinolone tx 45 4.79 1.33–17.25 0.017
KAN  Diet commercial 8 0.22 0.058–0.812 0.023
ATM  Previous quinolone tx 55 19.18 3.67–100.14 0.000
Legend: OR – odds ratio; CI – conﬁdence interval; tx – treatment; O. – owner; Prof. – professional; Health prof. – healthcare professional; AMP  – ampicillin;
; CAZ – c
omycin;AMC  – amoxicillin–clavulanic acid; CEF – cephalothin; FOX – cephoxitin
GEN  – gentamicin; NIT – nitrofurantoin; TET – tetracycline; STR – strept
kanamycin; IPM – imipenem; ATM – aztreonam.
category. In a study comprising fecal samples from 565
stray and 312 hospitalized dogs, Nam et al. (2010) reported
generally higher AMR  rates. However, according to Korea
Health Products Association data regarding the amount of
antimicrobials used in pets, this conclusion was previously
reached by the authors, who hypothesized that resistance
is related to the categories and elevated antimicrobial
consumption rates in the country.
Because no antimicrobial was administered to the
animals enrolled in the present study during the four
months prior to sampling, our results are consistent with
the hypothesis that the reversibility of resistance in the
absence of AM is a slow process, most likely due to com-
pensatory evolution and cost-free resistance mechanisms
(Andersson and Hughes, 2009). Although the Porto city
area follows the urban trend of longer pet longevity, bet-
ter veterinary care and widespread use of antibiotics in
companion animal treatments, there is no evidence that
these characteristics are different from those of other stud-
ied areas. It has been demonstrated, however, that the
Porto region suffers from a high level of environmental
contamination with antimicrobial resistance determinants
(Novais et al., 2005; Simões et al., 2010; Flores et al.,
2013); therefore, the acquisition of resistance may  be
multifactorial (Martínez, 2012), and environment contam-
ination exposure may  also contribute to the high AMR
rates.
Two variables inﬂuencing E. coli AMR  deserve spe-
cial attention because of their relationship with resistance
to several antimicrobials. These risk markers are prior
quinolone treatment and coprophagic habits, which are
discussed in detail below.eftazidime; CTX – cefotaxime; NAL – nalidixic acid; CIP – ciproﬂoxacin;
 SXT – trimethoprim–sulfamethoxazole; CHL – chloramphenicol; KAN –
During coprophagic behavior, the animal ingests gut
microﬂora, including multidrug-resistant E. coli strains,
from himself, which means a re-inoculation (autoco-
prophagy), or from other animals (allocoprophagy). Those
strains, particularly those from autocoprophagy, are
expected to be adapted for prolonged colonization. Fur-
thermore, feces from animals undergoing AM treatments,
particularly with poor oral bioavailability, may  contain
residual concentrations of the drug that are high enough to
pressure the emergence and dissemination of AMR  (Thaller
et al., 2010; Toutain et al., 2010). Finally, several studies
have shown that there is a high level of horizontal gene
transfer (HGT) within the intestine and that its warm and
nutrient-rich environment makes it an ideal location for
such a phenomenon (Lester et al., 2006; Hammerum and
Heuer, 2009; Jakobsson et al., 2010).
Among the 15 studied antimicrobials, 12 had resistance
rates related to previous quinolone treatments. Previous
quinolone exposure had previously been indicated as a risk
marker for the emergence of AMR  in E. coli isolated from
food animals (Moniri and Dastehgoli, 2005) and humans
(Cheong et al., 2001; McDonald et al., 2001; Lastours
et al., 2010). This occurrence has been explained by the
possible association of multiple antimicrobial resistance
genes on mobile genetic elements (Moreno et al., 2008;
Strahilevitz et al., 2009). Additionally, a strong association
of plasmid-mediated quinolone resistance (PMQR) deter-
minants with extended–spectrum––lactamases (ESBLs)
or AmpC–type––lactamases has been reported (Moreno
et al., 2008; Hammerum and Heuer, 2009; Strahilevitz et al.,
2009; Rawat and Nair, 2010). These two types of resis-



























































Aarestrup, F.M., 2004. Monitoring of antimicrobial resistance among food
animals: principles and limitations. J. Vet. Med. 51, 380–388.L.R. Leite-Martins et al. / Preventiv
long with genetic determinants of other antimicrobial
gents, such as aminoglycosides, trimethoprim, sulfona-
ides, tetracyclines and chloramphenicol (Jacoby, 2009;
trahilevitz et al., 2009; Rawat and Nair, 2010; Zhao et al.,
010).
The signiﬁcantly higher risk for ampicillin and
moxicillin–clavulanic acid resistance in pets whose
wners are healthcare workers may  be due to the com-
ination of two driving forces. First, because genetic
eterminants for aminopenicillin resistance often circu-
ate among medical staff and facilities, pets are at increased
isk of acquiring antimicrobial-resistant E. coli from these
wners (Hammerum and Heuer, 2009; Kalter et al., 2010;
artins da Costa et al., 2013). Second, the transfer of
peciﬁc resistance determinants to endogenous strains
ay  be signiﬁcantly enhanced by recurrent exposure to
he most prescribed oral antimicrobial drug in Portugal,
amely amoxicillin–clavulanic acid (DGAV, 2011).
At the univariable level, the model used in the present
tudy showed a clear and positive association between pre-
ious antimicrobial exposure and AMR. After our results
Table 5), it can be hypothesized that animals with a rel-
vant clinical background (pe, previously exposed to an
ntimicrobial treatment) harbor more resistant E. coli iso-
ates. This was also reported by Moyaert et al. (2006), whose
ork with hospitalized animals showed frequencies of
MR  similar to the rates found in our study, which included
early two thirds (62%) of patients with chronic con-
itions recurrently exposed to antimicrobial treatments.
 similar effect was observed with the age variable for
he -lactamics ampicillin, amoxicillin–clavulanic acid and
ephalothin. Therefore, younger and healthy animals carry
ess resistant E. coli strains, which may  be related to fewer
pportunities of contact with antimicrobials. This, added to
ewer cases of coprophagic habits, is also a plausible expla-
ation for the lower prevalence of antibiotic resistance in
ats compared to dogs, which exhibit a 5.16-fold higher
dds of carrying ampicillin-resistant E. coli.
Finally, at the univariable level, the difference in the
isk for contamination with multidrug-resistant E. coli in
utdoor compared with indoor animals was not statis-
ically signiﬁcant. However, as shown by Boothe (2012),
ale gender was considered a risk marker for resistance to
mpicillin and chloramphenicol.
The limitations of the study are primarily related to
he number of pets enrolled, which was not calculated
n advance because the purpose was to include the most
nimals possible given the time and resources available.
owever, because the selection process was random, the
ets studied represent the hospital population and ensure
n important factor of external validity. The statistical anal-
sis provides the necessary signiﬁcance to assess the risk
arkers, taking account of the sample size. The microbio-
ogical isolation, identiﬁcation and antimicrobial resistance
etermination followed internal quality control proce-
ures to ensure reproducibility (consolidated methods
erformed by trained personnel) and accuracy (quality
ontrol of isolation and antimicrobial resistance media and
nternal control strains with known resistance patterns).
In the questionnaire, the section “Previous antimicro-
ial treatments” was designed to record the antimicrobialsnary Medicine 117 (2014) 28–39 37
commercial name. However, after the data analyses, it
came clear that the high variety of antimicrobial drugs
used by the owners hindered the statistical study. So, it
was decided to merge this data into a categorical vari-
able with three levels, as follows: “none”, “just one” and
“two or more” antimicrobial treatments. To overcome the
problem of memory bias, the authors decided to draw the
attention of the owner on quinolones, as a group of par-
ticular importance to the study, by presenting them a list
of commercial names from which they would recognize a
particular one if it was the case. Despite the fact that topical
and/or ear treatments information has also been collected
with the questionnaire, considering that these treatments
were scarce and the microorganisms studied were com-
mensal from feces, the authors decided not to include such
data into the analysis. Even though the evaluation of its
indirect inﬂuence at the antimicrobial resistance has not
been possible, it could be interesting.
5. Conclusion
The present survey showed an increased risk of AMR  in
enteric E. coli strains from pets with a record of previous
quinolone treatments, which is consistent with the results
of several other studies in different animal species. The pets
displaying coprophagic behavior showed an increased risk
of AMR  in enteric E. coli strains, which highlight the role of
veterinarians in alerting and educating pet owners in order
to prevent and limit such behavior. Other markers, such as
gender, species, and reason for check-up, were statistically
signiﬁcant for a small number of antimicrobials. Additional
studies of AMR  risk markers are necessary.
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